Abcam and TTP Labtech collaborate to develop sol-R reagent kits
Assay-ready kits will incorporate fully-validated, industry-leading recombinant antibody technology for high throughput research.
TTP Labtech and Abcam has announced a collaboration to further develop reagent kits for the quantification of secreted proteins in multiplexed screening assays.
Following the successful launch last year of sol-R coded beads, TTP Labtech is working with Abcam to meet customer needs by developing assay ready kits which enable researchers to deliver data driven decisions faster and with confidence. The sol-R reagent kits will offer Abcam’s highly validated and quality assured antibodies including recombinant antibody pairs, combined with the reliability of sol-R coded beads and mirrorball fluorescence cytometry technology from TTP Labtech for sample analysis.
Joby Jenkins, director – product strategy, TTP Labtech, commented: “Our sol-R coded beads are designed for secreted protein quantification in multiplexed no-wash immunoassay screens. Working with Abcam on the development of the sol-R reagent kits enables us to combine their advanced antibody technology and reagent expertise with our sol-R bead technology to provide convenient off-the-shelf kits. Since the kits are validated on TTP Labtech’s mirrorball plate-based fluorescent cytometer, repeated wash steps associated with traditional sandwich ELISA’s are no longer necessary, thereby significantly reducing assay times, while delivering data integrity.”
John Baker, Senior Vice President Portfolio and Business Development, at Abcam, said: “The integration of Abcam’s high quality antibody technology with TTP Labtech’s sol-R Reagents will deliver reproducibility, quality and efficiency to life science researchers, accelerating their research. The new kits have been designed for researchers carrying out high-throughput immunoassays including drug discovery in biotech, pharma and contract research organisations.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance